Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Bone Marrow Cytokines Concentrations in Myelodysplastic Neoplasms: Its Correlation with the Immune Populations and Clonal Hematopoiesis

Antonieta Molero Yordi, Soraya Peralta Garzón, Laura Gallur, Barbara Tazon, Daniel Medina, Victor Navarro Garces, Maria Julia Montoro, Silvia Saumell, Tamara Jimenez, Félix López Cadenas, Teresa Ezponda, Ana Alfonso Pierola, Felipe Prosper, Maria Diez-Campelo, Olga Salamero, Ana Pérez González, Sara Garrido Paniagua, David Valcarcel

Blood (2023) 142 (Supplement 1): 6457.

https://doi.org/10.1182/blood-2023-185616

Published: 2023

Journal Articles

Role and Prevalence of Risk Factors That Trigger Therapy Related Myeloid Neoplasms (TRMN) in Patients with Previous Treated Breast Cancer

Oriol Calvete, Rashmi Kanagal-Shamanna, Julia Mestre, Guillermo Montalban-Bravo, Courtney D. DiNardo, Koji Sasaki, Jessica Aranda, Pamela Acha, Blanca Xicoy, Ana Pérez González, Laura Palomo, Maria Julia Montoro, Mireia Margeli, Francesc Sole

Blood (2023) 142 (Supplement 1): 4593.

https://doi.org/10.1182/blood-2023-188887

Published: 2023

Journal Articles

Prevalence, Dynamics and Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Newly Diagnosed Cancer Patients

Blood (2023) 142 (Supplement 1): 5593.

https://doi.org/10.1182/blood-2023-189503

Published: 2023

Journal Articles

Impact of Antibacterial Prophylaxis on Morbidity-Mortality of Patients with Myeloid Neoplasms Treated with Non-Intensive Venetoclax Combinations

Blood (2023) 142 (Supplement 1): 4270.

https://doi.org/10.1182/blood-2023-186762

Published: 2023

Journal Articles

A Real-World Analysis of Immune Thrombotic Thrombocytopenic Purpura: Comparing Clinical Outcomes of Conventional Treatment Vs Addition of Caplacizumab, a Single-Center Experience

Valeria Estefania Delgado Pinos, Pilar Lancho Lavilla, Marta Moreno Carbonell, Ana Pérez Corral, Cristina Pascual Izquierdo

Blood (2023) 142 (Supplement 1): 2634.

https://doi.org/10.1182/blood-2023-190922

Published: 2023

Journal Articles

Results of Treatment Approaches in Myeloid Neoplasms According to TP53 Allelic Status (Multi-hit vs Monoallelic), a Real World Analysis

Maria Sola, Francisco Beas, Laura Palomo, Mar Tormo, Ana Riera, Nicolas Díaz Varela, Teresa Bernal, Sara García, Concepción Fernández, Nieves Garcia-Gisbert, Félix López Cadenas, Barbara Tazon, Adoracion Blanco, Sara Garrido Paniagua, Ana Pérez González, Andres Jerez, Julia Montoro, Olga Salamero, David Valcarcel

Blood (2023) 142 (Supplement 1): 3227.

https://doi.org/10.1182/blood-2023-187101

Published: 2023

Journal Articles

Clinical Impact of the New Bone Marrow Blasts Cutoff Defined By the International Classification Consortium (ICC) in Myeloid Neoplasms with Mutated TP53 gene

Blood (2023) 142 (Supplement 1): 3235.

https://doi.org/10.1182/blood-2023-181698

Published: 2023

Journal Articles

Incidence, Risk Factors and Clinical Impact of Sars-Cov-2 Prolonged Viral Shedding in Patients Diagnosed with Hematologic Malignancies

Blood (2023) 142 (Supplement 1): 3927.

https://doi.org/10.1182/blood-2023-191146

Published: 2023

Journal Articles

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Blood (2023) 142 (Supplement 1): 1858.

https://doi.org/10.1182/blood-2023-186777

Published: 2023

Journal Articles

Haploidentical Donor Vs. Mismatch Unrelated Donor in Reduced Intensity Conditioning Transplant: A Study from the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH-TC)

Blood (2022) 140 (Supplement 1): 7631–7633.

https://doi.org/10.1182/blood-2022-167747

Published: 2022

Journal Articles

IPSS-M Applicability and Clinical Impact in Decision-Making Process in Real-Life Clinical Practice

Sandra Novoa Jáuregui, Laura Palomo, Ana Pérez, Bárbara Tazón, Maria Julia Montoro, Adoracion Blanco, Silvia Saumell, Laura Gallur, Eugenia Rivero, Sara Garrido, Marc Bosch Schips, Sofia Laura Muzio, Margarita Ortega, Antonieta Molero Yordi, Francesc Bosch, David Valcárcel

Blood (2022) 140 (Supplement 1): 6966–6967.

https://doi.org/10.1182/blood-2022-168705

Published: 2022

Journal Articles

Iadademstat Combination with Azacitidine Is a Safe and Effective Treatment in First Line Acute Myeloid Leukemia. Final Results of the Alice Trial

Olga Salamero, Tim C.P Somervaille, Antonieta Molero, Evelyn Acuña-Cruz, Jose A. Perez-Simon, Rosa Coll, Montserrat Arnan, Brayan Merchan, Ana Perez, Isabel Cano, Rebeca Rodríguez-Veiga, Mabel Arevalo, Sonia Gutierrez, Carlos Buesa, Douglas V Faller, Francesc Bosch, Pau Montesinos

Blood (2022) 140 (Supplement 1): 1711–1713.

https://doi.org/10.1182/blood-2022-168945

Published: 2022

Journal Articles

Characterization of Terminal Erythroid Differentiation (TED) and Its Prognosis Impact Inpatients with Myelodysplastic Syndrome (MDS)

Marc Bosch Schips, Julia Montoro, Félix López Cadenas, Alba Mesa, Víctor Navarro Garcés, Ana Pérez, Laura Gallur, Silvia Saumell, Mayda Navarrete, Margarita Ortega, Bárbara Tazón, Antonieta Molero, Olga Salamero, Sandra Novoa Jáuregui, Sofia Laura Muzio, Francesc Bosch, David Valcárcel

Blood (2022) 140 (Supplement 1): 12308–12310.

https://doi.org/10.1182/blood-2022-157434

Published: 2022

Journal Articles

Bone Marrow Microenvironment Changes in Myelodysplastic Neoplasms and Its Relationship with Clonal Hematopoiesis and Disease Progression

Antonieta Molero Yordi, Soraya Peralta, Laura Gallur, Bárbara Tazón, Víctor Navarro Garcés, Silvia Saumell, Maria Julia Montoro, Olga Salamero, Ana Pérez González, Sara Garrido, Maria Sola, Tamara Jimenez, Félix López Cadenas, Teresa Ezponda, Ana Alfonso-Pierola, Lídia Altimiras, Maria Diez-Campelo, Felipe Prosper, David Valcárcel

Blood (2022) 140 (Supplement 1): 4024–4025.

https://doi.org/10.1182/blood-2022-163188

Published: 2022

Journal Articles

Patients with Acute Myeloid Leukemia on Non-Intensive Therapy: Applicability of the European Leukemia Net Risk Classification

Pablo Silva, Jon Badiola, Reyes María Martín-Rojas, Ignacio Gómez-Centurión, Gabriela Rodríguez-Macias, Marina Gómez-Llobell, Carolina Martínez-Laperche, Diego Carbonell, Mónica Ballesteros, Ana Pérez-Corral, María Chicano, Patricia Font Lopez, Isabel Pérez-Sánchez, Ismael Buño, Javier Anguita, Mi Kwon, José Luis Díez-Martín

Blood (2021) 138 (Supplement 1): 3382.

https://doi.org/10.1182/blood-2021-153202

Published: 2021

Journal Articles

Day 14 Measurable Residual Disease As a Predictor of Post-Induction Response in Patients with Acute Myeloid Leukemia

Reyes María Martín-Rojas, Jon Badiola, Pablo Silva De Tena, Ana Pérez-Corral, Ignacio Gómez-Centurión, Gabriela Rodríguez-Macias, Mónica Ballesteros, Carolina Martínez-Laperche, Patricia Font Lopez, Isabel Pérez-Sánchez, Ismael Buño, Javier Anguita, Mi Kwon, Jose L. Diez-Martin

Blood (2021) 138 (Supplement 1): 1287.

https://doi.org/10.1182/blood-2021-150808

Published: 2021

Journal Articles

Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients (ALICE Trial)

Olga Salamero, Tim C.P Somervaille, Antonieta Molero, Evelyn Acuña-Cruz, Jose Pérez-Simón, Rosa Coll, Montserrat Arnan Sangerman, Brayan Merchan, Ana Perez, Isabel Cano, Rebeca Rodríguez-Veiga, Sonia Gutierrez, Carlos Buesa, Francesc Bosch, Pau Montesinos

Blood (2021) 138 (Supplement 1): 3376.

https://doi.org/10.1182/blood-2021-152183

Published: 2021

Journal Articles

Microenvironment Profiling in Myelodysplastic Syndromes and Its Relationship to Clonal Hematopoiesis and Disease Progression

Antonieta Molero Yordi, Bárbara Tazón, Laura Gallur, Silvia Saumell, Tamara Jimenez, Teresa Ezponda, Maria Julia Montoro, Félix López Cadenas, Lídia Altimiras, Carla Sánchez Ruiz, Ana Alfonso, Olga Salamero, Ana Pérez, Soraya Peralta, Maria Diez-Campelo, Felipe Prosper, Francesc Bosch, David Valcarcel

Blood (2021) 138 (Supplement 1): 4650.

https://doi.org/10.1182/blood-2021-150104

Published: 2021

Journal Articles

Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy

Gloria Iacoboni, MD, Marc Simo, MD, Guillermo Villacampa, Eva Catala, Cecilia Carpio, MD, Candido Diaz-Lagares, MD, Angela Vidal-Jordana, MD, Sabela Bobillo, MD, Ana Marin-Niebla, MD PhD, Ana Perez, MD, Moraima Jiménez, Pau Abrisqueta, MD PhD, David Valcárcel, MD PhD, Francesc Bosch, MD PhD, Pere Barba, MD PhD

Blood (2020) 136 (Supplement 1): 27–29.

https://doi.org/10.1182/blood-2020-141777

Published: 2020

Journal Articles

Real World Efficacy Evaluation of Branded and Copy Imatinib in Chronic Myeloid Leukemia: A Retrospective Multicentric Study from Argentina

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-137792

Published: 2020

NARROW

Bone Marrow Cytokines Concentrations in Myelodysplastic Neoplasms: Its Correlation with the Immune Populations and Clonal Hematopoiesis

Role and Prevalence of Risk Factors That Trigger Therapy Related Myeloid Neoplasms (TRMN) in Patients with Previous Treated Breast Cancer

Prevalence, Dynamics and Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Newly Diagnosed Cancer Patients

Impact of Antibacterial Prophylaxis on Morbidity-Mortality of Patients with Myeloid Neoplasms Treated with Non-Intensive Venetoclax Combinations

A Real-World Analysis of Immune Thrombotic Thrombocytopenic Purpura: Comparing Clinical Outcomes of Conventional Treatment Vs Addition of Caplacizumab, a Single-Center Experience

Results of Treatment Approaches in Myeloid Neoplasms According to TP53 Allelic Status (Multi-hit vs Monoallelic), a Real World Analysis

Clinical Impact of the New Bone Marrow Blasts Cutoff Defined By the International Classification Consortium (ICC) in Myeloid Neoplasms with Mutated TP53 gene

Incidence, Risk Factors and Clinical Impact of Sars-Cov-2 Prolonged Viral Shedding in Patients Diagnosed with Hematologic Malignancies

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Haploidentical Donor Vs. Mismatch Unrelated Donor in Reduced Intensity Conditioning Transplant: A Study from the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH-TC)

IPSS-M Applicability and Clinical Impact in Decision-Making Process in Real-Life Clinical Practice

Iadademstat Combination with Azacitidine Is a Safe and Effective Treatment in First Line Acute Myeloid Leukemia. Final Results of the Alice Trial

Characterization of Terminal Erythroid Differentiation (TED) and Its Prognosis Impact Inpatients with Myelodysplastic Syndrome (MDS)

Bone Marrow Microenvironment Changes in Myelodysplastic Neoplasms and Its Relationship with Clonal Hematopoiesis and Disease Progression

Patients with Acute Myeloid Leukemia on Non-Intensive Therapy: Applicability of the European Leukemia Net Risk Classification

Day 14 Measurable Residual Disease As a Predictor of Post-Induction Response in Patients with Acute Myeloid Leukemia

Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients (ALICE Trial)

Microenvironment Profiling in Myelodysplastic Syndromes and Its Relationship to Clonal Hematopoiesis and Disease Progression

Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy

Real World Efficacy Evaluation of Branded and Copy Imatinib in Chronic Myeloid Leukemia: A Retrospective Multicentric Study from Argentina

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only